Christian Herzog

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8955533/publications.pdf

Version: 2024-02-01

31	811	430754	501076
papers	citations	18 h-index	28 g-index

32	32	32	876
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Immunogenicity and Safety of a Virosomal Hepatitis A Vaccine (EpaxalÂ®) in the Elderly. Journal of Travel Medicine, 2006, 13, 78-83.	1.4	69
2	Efficacy of Virosome Hepatitis A Vaccine in Young Children in Nicaragua: Randomized Placeboâ€Controlled Trial. Journal of Infectious Diseases, 2003, 188, 671-677.	1.9	67
3	Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study. Travel Medicine and Infectious Disease, 2014, 12, 134-142.	1.5	67
4	Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature. Expert Review of Vaccines, 2014, 13, 399-415.	2.0	48
5	IMMUNOGENICITY AND SAFETY OF BERNA-YF COMPARED WITH TWO OTHER 17D YELLOW FEVER VACCINES IN A PHASE 3 CLINICAL TRIAL. American Journal of Tropical Medicine and Hygiene, 2005, 72, 339-346.	0.6	45
6	Predicted 30â€year protection after vaccination with an aluminumâ€free virosomal hepatitis A vaccine. Journal of Medical Virology, 2010, 82, 1629-1634.	2.5	43
7	Successful Memory Response following a Booster Dose with a Virosome-Formulated Hepatitis A Vaccine Delayed Up to 11 Years. Vaccine Journal, 2011, 18, 885-887.	3.2	38
8	Rate, intensity, and duration of local reactions to a virosome-adjuvanted vs. an aluminium-adsorbed hepatitis A vaccine in UK travellers. Travel Medicine and Infectious Disease, 2006, 4, 313-318.	1.5	36
9	Reduced-Dose Intradermal Vaccination against Hepatitis A with an Aluminum-Free Vaccine Is Immunogenic and Can Lower Costs. Clinical Infectious Diseases, 2005, 41, 1537-1540.	2.9	34
10	Concomitant Administration of a Virosome-Adjuvanted Hepatitis A Vaccine With Routine Childhood Vaccines at Age Twelve to Fifteen Months: A Randomized Controlled Trial. Pediatric Infectious Disease Journal, 2007, 26, 787-793.	1.1	34
11	Immunogenicity and Safety of a Pediatric Dose of a Virosome-Adjuvanted Hepatitis A Vaccine. Pediatric Infectious Disease Journal, 2007, 26, 705-710.	1.1	34
12	Virosomal Hepatitis A Vaccine: Comparing Intradermal and Subcutaneous With Intramuscular Administration. Journal of Travel Medicine, 2009, 16, 413-419.	1.4	30
13	The phylogeny of yellow fever virus 17D vaccines. Vaccine, 2012, 30, 989-994.	1.7	29
14	An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression â€“ A prospective, open-label, multi-center study. Travel Medicine and Infectious Disease, 2018, 21, 43-50.	1.5	29
15	Hepatitis A vaccination and its immunological and epidemiological long-term effects â€“ a review of the evidence. Human Vaccines and Immunotherapeutics, 2021, 17, 1496-1519.	1.4	29
16	Successful Booster Antibody Response up to 54 Months after Single Primary Vaccination with Virosome-Formulated, Aluminum-Free Hepatitis A Vaccine. Clinical Infectious Diseases, 2003, 37, e126-e128.	2.9	27
17	Single-Dose Hepatitis A Immunization: 7.5-Year Observational Pilot Study in Nicaraguan Children to Assess Protective Effectiveness and Humoral Immune Memory Response. Journal of Infectious Diseases, 2016, 214, 1498-1506.	1.9	25
18	Kinetics of maternally acquired anti-hepatitis A antibodies: Prediction of waning based on maternal or cord blood antibody levels. Vaccine, 2013, 31, 1490-1495.	1.7	22

#	Article	IF	Citations
19	Successful comeback of the single-dose live oral cholera vaccine CVD 103-HgR. Travel Medicine and Infectious Disease, 2016, 14, 373-377.	1.5	19
20	Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseasesâ€"a prospective multi-centre cohort study. Rheumatology, 2019, 58, 1585-1596.	0.9	19
21	Detection of antibodies to HAV 3C proteinase in experimentally infected chimpanzees and in naturally infected children. Vaccine, 2001, 19, 2878-2883.	1.7	17
22	Real-life versus package insert: A post-marketing study on adverse-event rates of the virosomal hepatitis A vaccine EpaxalÂ® in healthy travellers. Vaccine, 2011, 29, 5000-5006.	1.7	12
23	Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae. Vaccine, 2014, 32, 544-551.	1.7	10
24	Compatible Concurrent Administration of Yellow Fever 17D Vaccine with Oral, Live, Attenuated Cholera CVD103â€HgR and Typhoid Ty21a Vaccines. Journal of Infectious Diseases, 1999, 179, 522-524.	1.9	9
25	Decreasing Risk of Hepatitis A Infection in LeÃ³n, Nicaragua: Evidence from Cross-Sectional and Longitudinal Seroepidemiology Studies. PLoS ONE, 2014, 9, e87643.	1.1	9
26	Changing from whole-cell to acellular pertussis vaccines would trade superior tolerability for inferior protection. Expert Review of Vaccines, 2015, 14, 1065-1072.	2.0	3
27	Immune memory persistence is well documented for hepatitis A vaccines. Vaccine, 2021, 39, 4775-4776.	1.7	3
28	Surveying adverse event rates: lessons from a virosomal hepatitis A vaccine. Expert Review of Vaccines, 2012, 11, 383-385.	2.0	1
29	Serologic differential diagnosis of hepatitis A virus (HAV) infected and vaccinated individuals: How long persist antibodies to non-structural HAV proteins?. Vaccine, 2018, 36, 3883-3884.	1.7	1
30	Hepatitis A vaccination in immunocompromised patients â€“ the need for individualized vaccination strategies and correct methodology. Travel Medicine and Infectious Disease, 2019, 32, 101526.	1.5	1
31	Clinical, serological and epidemiological features of hepatitis A in LeÃ³n, Nicaragua. PeerJ, 2021, 9, e11516.	0.9	0